Eicosanoids and the liver

Decker, 1985, Eicosanoids, signal molecules of liver cells, Semin Liv Dis, 5, 175, 10.1055/s-2008-1063921

Ramwell, 1970, Biological significance of the prostaglandins, Recent Prog Horm Res, 26, 139

Huber M, Keppler D. Eicosanoids and the liver. In: Popper H, Schaffner, editors. Progress in liver diseases, Volume 9. Philadelphia: Saunders, 1990. p. 117.

Rush, 1986, Studies on the mechanism of the protective action of 16,16 dimethyl-PGE2 in carbon tetrachloride-induced acute hepatic injury in the rat, Prostaglandins, 32, 439, 10.1016/0090-6980(86)90011-0

Araki, 1980, Cytoprotective actions of prostacyclin during hypoxia in the isolated profused cat liver, Am J Physiol, 238, H176

Davis, 1974, Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen, Life Sci, 14, 2099, 10.1016/0024-3205(74)90092-7

Ogawa, 1988, Inhibitory effects of prostaglandin E1 on T-cell mediated cytotoxicity against isolated mouse liver cells, Gastroenterology, 94, 1024, 10.1016/0016-5085(88)90562-8

Tiegs, 1988, Leukotriene mediated liver injury, Biochem Pharmacol, 37, 2569, 10.1016/0006-2952(88)90248-1

Hagmann, 1987, Leukotrienes as mediators in frog virus 3-induced hepatitis in rats, Hepatology, 7, 732, 10.1002/hep.1840070419

Sinclair, 1990, Eicosanoids and the liver, Ital J Gastroenterol, 22, 205

Peltekian, 1996, Prostaglandins in liver failure and transplantation, Prostaglandins in liver transplantation research group. Liver Transpl Surg, 2, 171, 10.1002/lt.500020302

Quiroga, 1993, Liver cytoprotection by prostaglandins, Pharmacol Ther, 58, 67, 10.1016/0163-7258(93)90067-N

Kujubu, 1991, TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homolog, J Biol Chem, 266, 12866, 10.1016/S0021-9258(18)98774-0

Holtzman, 1992, Identification of a pharmacologically distinct prostaglandin H synthetase in cultured epithelial cells, J Biol Chem, 267, 21438, 10.1016/S0021-9258(19)36629-3

Sirois, 1992, Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthetase in rat pre-ovulating follicles, J Biol Chem, 267, 11586, 10.1016/S0021-9258(19)49951-1

Goppelt-Streube, 1995, Regulation of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzyme expression, Prostaglandins Leukot Essent Fatty Acids, 52, 213, 10.1016/0952-3278(95)90039-X

Higgs, 1983, Inhibition of cyclooxygenase and lipoxygenase, Br Med Bull, 39, 265, 10.1093/oxfordjournals.bmb.a071831

Hagmann, 1991, The sensitized liver represents a rich source of endogenous leukotrienes, Hepatology, 13, 482, 10.1002/hep.1840130316

Piper, 1984, Formations and actions of leukotrienes, Physiol Rev, 64, 744, 10.1152/physrev.1984.64.2.744

Capdevila, 1984, Arachidonic acid epoxidation, Arch Biochem Biophys, 231, 511, 10.1016/0003-9861(84)90415-6

Fitzpatrick, 1988, Cytochrome P450 metabolism of arachidonic acid, Pharmacol Rev, 40, 229

Sacerdoti, 1999, CYP450-dependent epoxyeicosatrenoic acids (EETs) may participate in the pathophysiology of portal hypertension by differentially modulating portal and mesenteric arterial resistance in cirrhotic rats, Hepatology, 30, A307

Brouwer, 1988, Isolation and culture of Kupffer cells from human liver. Ultrastructure, endocytosis and prostaglandin synthesis, J Hepatol, 6, 36, 10.1016/S0168-8278(88)80460-4

Birmelin, 1984, Synthesis of prostanoids and cyclic nucleotides by phagocytosing rat Kupffer cells, Eur J Biochem, 142, 219, 10.1111/j.1432-1033.1984.tb08274.x

Aderem, 1986, Bacterial lipopolysaccharides prime macrophages for enhanced release of arachidonic acid metabolites, J Exp Med, 164, 165, 10.1084/jem.164.1.165

Mieli–Vergani, 1992, Immunology and the liver, 95

Tran–Thi, 1987, Studies on synthesis and degradation of ecosanoids by rat hepatocytes in primary culture, J Hepatol, 5, 322, 10.1016/S0168-8278(87)80038-7

Needleman, 1986, Arachidonic acid metabolism, Annu Rev Biochem, 55, 69, 10.1146/annurev.bi.55.070186.000441

Sinclair, 1990, Mechanism of protective effect of prostaglandin E in murine hepatitis virus strain 3 infection, Adv Exp Med Biol, 276, 533, 10.1007/978-1-4684-5823-7_74

Fitzsimmons, 1988, Lipoxygenase inhibitors and leukotriene receptor antagnoists, 147

Nagai, 1989, Effect of OKY-046 and ONO-3708 on liver injury in mice, Jpn J Pharmacol, 51, 191, 10.1254/jjp.51.191

Nagai, 1989, The role of thromboxane A2 (TxA2) in liver injury in mice, Prostaglandins, 38, 439, 10.1016/0090-6980(89)90126-3

Hagmann, 1984, Role of peptide leukotrienes and their hepatobiliary elimination in endotoxin action, Circ Shock, 14, 223

Tiegs, 1988, Leukotriene-mediated liver injury, Biochem Pharmacol, 37, 2569, 10.1016/0006-2952(88)90248-1

Titos, 1999, Mechanisms of increased hepatic cysteinyl-leukotriene, Hepatology, 30, A294

Stachura, 1981, Prostaglandin protection of carbon tetrachloride induced liver cell necrosis in the rat, Gastroenterology, 81, 211, 10.1016/S0016-5085(81)80049-2

Guarner, 1983, In vivo and in vitro effects of arachidonic acid products on liver cell integrity following carbon tetrachloride poisoning, 75

Guarner, 1988, Reduction by prostacyclin of acetaminophen-induced toxicity in the mouse, Hepatology, 8, 248, 10.1002/hep.1840080210

Masaki, 1992, Hepatocyte membrane stabilization by prostaglandins E1 and E2, Gastroenterology, 102, 572, 10.1016/0016-5085(92)90105-8

Samuelsson, 1978, Prostaglandins and thromboxanes, Annu Rev Biochem, 47, 997, 10.1146/annurev.bi.47.070178.005025

Stachura, 1980, Cytoprotective effect of 16,16 dimethyl prostaglandin E2 and some drugs on an acute galactosamine induced liver damage in rat, Folia Histochem Cytochem (Krakow), 18, 311

Caldwell–Kankel, 1991, Kupffer cell activation and endothelial cell damage after storage of rat livers, Hepatology, 13, 83

Goto, 1992, Hepatic tissue oxygenation as a predictive indicator of ischemia-reperfusion liver injury, Hepatology, 15, 432, 10.1002/hep.1840150313

Koo, 1992, Contribution of no-reflow phenomenon to hepatic injury after ischemia-reperfusion, Hepatology, 15, 507, 10.1002/hep.1840150325

Combis, 1991, Eicosanoid and TMFα production by Kupffer cells following hypoxia-reoxygenation, Hepatology, 14, 51A

Sutto, 1991, Evaluation of liver endothelial cell (LEC) function using hyaluronic acid (HA) elimination during short cold ischemia, Hepatology, 14, 51A

Besse, 1989, Effect of PGI2 and thromboxane antagonist on liver ischemic injury, Eur Surg Res, 21, 213, 10.1159/000129026

Mora, 1987, Successful liver allograft function after 24 h preservation, Transplant Proc, 19, 3932

Iwata, 1999, Intraportal perfusion of prostaglandin E1 attenuates hepatic postischemic microcirculatory impairments in rats, J Gastroenterol Hepatol, 14, 634, 10.1046/j.1440-1746.1999.01929.x

Arai, 1999, cAMP mediates protective pre-conditioning of sinusoidal endothelial cells against storage/reperfusion injury, Hepatology, 30, A605

Abecassis, 1987, 16,16 dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection, J Clin Invest, 80, 881, 10.1172/JCI113147

Hagmann, 1987, Leukotrienes as mediators in frog virus 3-induced hepatitis in rats, Hepatology, 7, 732, 10.1002/hep.1840070419

Quiroga, 1999, Bile Salts, bile flow and cholestasis, 201

Mizoguchi, 1987, The protective effects of prostaglandin E1 in an experimental massive hepatic cell necrosis model, Hepatology, 7, 1184, 10.1002/hep.1840070603

Mahl, 1992, Prostaglandin E2 inhibits TNF production by Kupffer cells and prevents endotoxin induced mortality in mice, Gastroenterology, 102, A846

Tanaka, 1996, TNF production by rat Kupffer cells—regulation by lipopolysaccharide macrophage activating factor and prostaglandin E2, J Clin Lab Immunol, 48, 17

Sinclair, 1989, Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report, J Clin Invest, 84, 1063, 10.1172/JCI114268

Bernuau, 1990, Prostaglandin E1 (PGE1) has no beneficial effect in patients with either severe or fulminant hepatitis B, Hepatology, 12, 875

O’Brien, 1992, Prostaglandin E1 infusion improves survival of patients with fulminant hepatic failure, Gastroenterology, 102, A862

Sheiner, 1992, A randomized controlled trial of prostaglandin E2 (PGE2) in the treatment of fulminant hepatic failure (FHF), Hepatology, 16, 88A

Sterling, 1998, Treatment of fulminant hepatic failure with i.v. prostaglandin E1, Liver Transpl Surg, 4, 424, 10.1002/lt.500040501

Laffi, 1996, Lipid-derived autocoids, and renal function in liver cirrhosis, 307

Boyer, 1979, Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease, Gastroenterology, 77, 215, 10.1016/0016-5085(79)90268-3

Arroyo, 1991, Ascites, renal failure, and electrolyte disorders in cirrhosis. Pathogenesis, diagnosis, and treatment, 429

Huber, 1989, Analysis of cysteinyl leukotrienes in human urine, Eur J Clin Invest, 19, 53

Gines, 1993, Oral Misoprostol or i, v. prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol, 17, 220

Frei, 1999, Expression of COX1 and COX2 in primary biliary cirrhosis, Hepatology, 30, A1255

Lauterburg, 1975, Prostaglandin-induced choleresis in the rat, Experientia, 31, 1191, 10.1007/BF02326787

Kaminski, 1975, The effect of prostaglandin A1 and E1 on canine hepatic blood flow, J Surg Res, 18, 391, 10.1016/0022-4804(75)90099-2

Beckh, 1994, Direct regulation of bile secretion by prostaglandins in perfused rat liver, Hepatology, 19, 1208, 10.1002/hep.1840190519

Walker, 1983, Lymphokine tegulation of activated lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production, J Immunol, 130, 1770, 10.4049/jimmunol.130.4.1770

Rappaport, 1982, Prostaglandin E inhibits the production of human interleukin 2, J Exp Med, 155, 943, 10.1084/jem.155.3.943

Chouaib, 1985, Prostaglandin E1 acts on two distinct pathways of T-lymphocyte activation, J Immunol, 135, 1172, 10.4049/jimmunol.135.2.1172

Pollak, 1990, The immunosuppressive properties or new oral prostaglandin E1 analogs, Transplantation, 50, 834, 10.1097/00007890-199011000-00018

Moran, 1990, Prevention of acute raft rejection by the prostaglandin E1 analog Misoprostol in renal transplant recipients treated with cyclosporin and Prednisolone, New Engl J Med, 322, 1183, 10.1056/NEJM199004263221703

Curtis, 1993, Misoprostol in renal transplantation, Transplant Proc, 25, 602

Weir, 1991, The immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC-45622), Transplantation, 52, 1053, 10.1097/00007890-199112000-00021

Takaya S, Bronster O, Abu–Elmagd, et al. Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. Transplant Proc 1993;25:2381.

Quiroga, 1991, Cause and timing of first allograft failure in liver transplantation. A study of 177 consecutive patients, Hepatology, 14, 1054, 10.1002/hep.1840140618

McKeown, 1988, Sinusoidal lining cell damage, Transplantation, 46, 178, 10.1097/00007890-198808000-00001

Greig, 1989, Treatment of primary graft non-function with prostaglandin E1 results in increased graft and patient survival, Transplant Proc, 21, 2385

Skouteris, 1988, Regulation of the proliferation of primary rat hepatocytes by eicosanoids, J Cell Physiol, 135, 516, 10.1002/jcp.1041350321

Zublke, 1992, Color flow Doppler imaging during epoprostenol (PGI2) therapy of primary nonfunction following liver transplantation, Transplant Proc, 24, 1985

Tanchareon, 1992, Prostaglandin E1 treatment in orthoptic liver transplantation recipients, Transplant Proc, 24, 2248

Briegel, 1992, Primary graft nonfunction following orthotopic liver transplantation, Transplant Proc, 24, 2693

Grazi, 1994, Prostaglandin therapy in primary liver graft nonfunction after orthototic transplantation, Transplant Proc, 26, 3651

Fisher, 1994, Induction with OKT3 and prostaglandin E1 in liver transplantation, Transplant Sci, 4, S1

Hamamoto, 1994, Can adenine nucleotides predict primary non-function of the liver human liver homograft?, Transpl Int, 7, 89, 10.1111/j.1432-2277.1994.tb01226.x

Henley, 1995, A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation, Hepatology, 21, 366